A non-randomized, open-label, dose-finding, first-in-human trial of combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: transgene expression persists up to 17 months post-vector injection
Published in 2022 by
Yoshie Umemura,
Daniel Orringer,
Larry Junck,
Maria L. Varela,
Molly E. J. West,
Syed M. Faisal,
Andrea Comba,
Jason Heth,
Oren Sagher,
Denise Leung 
,
Aaron Mammoser,
Shawn Hervey-Jumper,
Daniel Zamler,
Viveka N. Yadav,
Patrick Dunn
and other authors.
,
Aaron Mammoser,
Shawn Hervey-Jumper,
Daniel Zamler,
Viveka N. Yadav,
Patrick Dunn
and other authors.
